Publication: 3616

Publication: 3616

Plasma protein biomarkers in advanced or metastatic colorectal cancer patients receiving chemotherapy with bevacizumab or cetuximab: Results from CALGB 80405 (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Clin Cancer Res vol 28 (13) 2779-2788

Year:: 2022
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 11

Parents:: 2467 2656 3016
Children:: None

Program:: TRP
Primary Committee:: Correl Sci NOS
Sec. Committees:

Pharmas:: Bristol-Myers, Genentech, Pfizer, and Sanofi
Grants:: U10CA180821, U10CA180882, U24CA196171, UG1CA233290, UG1CA233337, UG1CA233373, UG1CA189862, U10CA180820 (ECOG-ACRIN), UG1CA180830, U10CA180888 (SWOG)

Corr. Author:
Authors:: Andrew B. Nixon Alexander B. Sibley Yingmiao Liu Ace J. Hatch Chen Jiang Flora Mulkey Mark D. Starr John C. Brady Donna Niedzwiecki Alan P. Venook Luis Baez-Diaz Heinz-Josef Lenz Bert H. O'Neil Federico Innocenti Jeffrey A. Meyerhardt Eileen M O'Reilly Kouros Owzar Herbert I. Hurwitz

Networks:: CA011, CA824, LAPS-IN007, LAPS-MA036, LAPS-NC007, LAPS-NC010, LAPS-NY016

Study: CALGB-80405
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: predictive biomarker, prognostic biomarker, bevacizumab, cetuximab, metastatic colorectal cancer